In animal models of obesity, the administration of this dual GLP-1R/GCGR agonists resulted in better weight loss, lower glucose levels, and reduced food intake, compared to pure GLP-1r agonists alone [142,143,144]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.